A Single Institutional Experience Using Romiplostim to Treat Therapy-Related Thrombocytopenia in Pediatric Solid Tumor Patients Journal Article
| Authors: | Degliuomini, M. D.; Armstrong, K.; Curry, M.; Mauguen, A.; Modak, S.; Dunkel, I. J.; Slotkin, E. K.; Soff, G. A.; Mones, J. V.; Ortiz, M. V. |
| Article Title: | A Single Institutional Experience Using Romiplostim to Treat Therapy-Related Thrombocytopenia in Pediatric Solid Tumor Patients |
| Abstract: | Chemotherapy-induced thrombocytopenia (CIT) is a common toxicity in patients with cancer, leading to chemotherapy dose reductions and increased platelet transfusions. Although there are well-documented data using thrombopoietin receptor agonists (TPO-RA) in both adult CIT and pediatric immune thrombocytopenia, there is a paucity of data in pediatric CIT. This is a single institutional, retrospective study evaluating the use and safety of romiplostim in pediatric patients with solid tumors undergoing cancer treatment. Romiplostim was well tolerated and appeared to provide clinical benefit. This report advocates for further research using TPO-RA in pediatric patients being treated for cancer. |
| Keywords: | chemotherapy; chemotherapy-induced thrombocytopenia | pediatric oncology | platelet transfusions | thrombopoietin receptor agonists |
| Journal Title: | Pediatric Blood and Cancer |
| ISSN: | 1545-5009 |
| Publisher: | Wiley Periodicals, Inc |
| Publication status: | Online ahead of print |
| Date Published: | 2025-01-01 |
| Online Publication Date: | 2025-01-01 |
| Language: | English |
| ACCESSION: | WOS:001548158500001 |
| DOI: | 10.1002/pbc.31977 |
| PROVIDER: | wos |
| Notes: | Article; Early Access -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work